Symbols / SCPS
SCPS Chart
About
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 16.83K |
| Enterprise Value | -1.40M | Income | -8.70M | Sales | — |
| Book/sh | -0.24 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | 0.15 | EV/Sales | — | Quick Ratio | 0.03 |
| Current Ratio | 0.04 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.41 | EPS next Y | -1.23 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2021-11-12 17:00 | ROA | -5.38% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 42.08M |
| Shs Float | 34.22M | Short Float | 0.25% | Short Ratio | 0.22 |
| Short Interest | — | 52W High | 0.01 | 52W Low | 0.00 |
| Beta | 31.08 | Avg Volume | 1.43K | Volume | 47.08K |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$0.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2021-02-16 | init | Benchmark | — → Speculative Buy | $20 |
- ZEST Turns AWS Policies Into a Defense Tool for Cloud Security Teams - ChannelE2E Wed, 30 Jul 2025 07
- 19-year-old UCF student running for Seminole County School Board - WKMG Wed, 14 Jan 2026 08
- NoVA School District Adds Weapons Screening at Football Games - Northern Virginia Magazine Mon, 22 Sep 2025 07
- A singular focus: Making single-cell proteins a fixture on the aquaculture feed ingredient menu - Global Seafood Alliance Mon, 12 May 2025 07
- Shelby County High School on lockdown after bomb threat. Students reported safe. - Lexington Herald Leader Wed, 27 Aug 2025 07
- A Prominent OpenAI Investor Appears to Be Suffering a ChatGPT-Related Mental Health Crisis, His Peers Say - Futurism Fri, 18 Jul 2025 07
- Making the best of the new EU Social Climate Fund - Bruegel hu, 03 Apr 2025 07
- Fictor, who attempted to acquire Master, changes its fundraising method amid payment delays - NeoFeed ue, 13 Jan 2026 22
- Digitizing Your SCP: A Modular Approach to Medical Content - Veeva Fri, 15 Nov 2024 20
- Tata Steel shares in focus today; here’s why - Business Today Wed, 24 Dec 2025 08
- Seminole parents turn sour over candy sold at middle school - Orlando Sentinel Fri, 21 Apr 2023 07
- Fitch affirms ratings on Nakilat Inc’s $1.15bn debts| Gulf Times - Gulf Times Wed, 12 Mar 2025 07
- 25 Top Tokens May Be Commodities, VanEck Analysis Reveals - VanEck Fri, 07 Jul 2023 07
- Graphic novel about one of the most epic SCP Foundation entries - Boing Boing Sat, 12 Jun 2021 07
- Lupin Acquires Southern Cross Pharma in Australia - Lupin | Press Release - lupin.com Fri, 30 Jul 2021 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 |
| NormalizedEBITDA | -11.71M | -27.63M |
| TotalUnusualItems | 1.46M | |
| TotalUnusualItemsExcludingGoodwill | 1.46M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.61M | -26.95M |
| ReconciledDepreciation | 1.73K | 1.50K |
| EBITDA | -11.71M | -26.18M |
| EBIT | -11.71M | -26.18M |
| NetInterestIncome | 0.00 | -774.68K |
| InterestExpense | 0.00 | 774.68K |
| NormalizedIncome | -11.61M | -28.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.61M | -26.95M |
| TotalExpenses | 11.71M | 27.63M |
| TotalOperatingIncomeAsReported | -11.71M | -27.63M |
| DilutedAverageShares | 21.09M | 17.25M |
| BasicAverageShares | 21.09M | 17.25M |
| DilutedEPS | -0.55 | -1.56 |
| BasicEPS | -0.55 | -1.56 |
| DilutedNIAvailtoComStockholders | -11.61M | -26.95M |
| NetIncomeCommonStockholders | -11.61M | -26.95M |
| NetIncome | -11.61M | -26.95M |
| MinorityInterests | 105.05K | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -11.71M | -26.95M |
| NetIncomeContinuousOperations | -11.71M | -26.95M |
| PretaxIncome | -11.71M | -26.95M |
| OtherIncomeExpense | 1.46M | |
| GainOnSaleOfSecurity | 1.46M | |
| NetNonOperatingInterestIncomeExpense | 0.00 | -774.68K |
| InterestExpenseNonOperating | 0.00 | 774.68K |
| OperatingIncome | -11.71M | -27.63M |
| OperatingExpense | 11.71M | 27.63M |
| ResearchAndDevelopment | 2.68M | 15.02M |
| SellingGeneralAndAdministration | 9.03M | 12.61M |
| GeneralAndAdministrativeExpense | 9.03M | 12.61M |
| OtherGandA | 9.03M | 12.61M |
| TotalRevenue | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| OrdinarySharesNumber | 21.09M | 21.09M |
| ShareIssued | 21.09M | 21.09M |
| TangibleBookValue | -6.56M | 4.02M |
| InvestedCapital | -6.56M | 4.02M |
| WorkingCapital | -7.06M | 4.01M |
| NetTangibleAssets | -6.56M | 4.02M |
| CommonStockEquity | -6.56M | 4.02M |
| TotalCapitalization | -6.56M | 4.02M |
| TotalEquityGrossMinorityInterest | -7.06M | 4.02M |
| MinorityInterest | -497.84K | 0.00 |
| StockholdersEquity | -6.56M | 4.02M |
| OtherEquityInterest | -33.95K | |
| GainsLossesNotAffectingRetainedEarnings | -4.95K | -86.65K |
| OtherEquityAdjustments | -4.95K | -86.65K |
| RetainedEarnings | -53.06M | -41.46M |
| AdditionalPaidInCapital | 46.52M | 45.54M |
| CapitalStock | 21.09K | 21.09K |
| CommonStock | 21.09K | 21.09K |
| PreferredStock | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 7.45M | 4.17M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 |
| CurrentLiabilities | 7.45M | 4.17M |
| OtherCurrentLiabilities | 252.51K | |
| PayablesAndAccruedExpenses | 7.20M | 4.17M |
| CurrentAccruedExpenses | 7.03M | 4.05M |
| InterestPayable | 0.00 | |
| Payables | 175.64K | 116.13K |
| OtherPayable | 175.64K | 116.13K |
| TotalAssets | 392.26K | 8.19M |
| TotalNonCurrentAssets | 2.27K | 2.84K |
| NetPPE | 2.27K | 2.84K |
| CurrentAssets | 390.00K | 8.18M |
| OtherCurrentAssets | 265.43K | 241.90K |
| PrepaidAssets | 241.90K | |
| CashCashEquivalentsAndShortTermInvestments | 124.58K | 7.94M |
| CashAndCashEquivalents | 124.58K | 7.94M |
| CashFinancial | 124.58K | 7.94M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | -8.13M | -11.43M |
| RepaymentOfDebt | 0.00 | -104.50K |
| IssuanceOfDebt | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 20.10M |
| CapitalExpenditure | -1.55K | -2.00K |
| InterestPaidSupplementalData | 0.00 | 25.04K |
| IncomeTaxPaidSupplementalData | 0.00 | |
| EndCashPosition | 124.58K | 7.94M |
| BeginningCashPosition | 7.94M | 1.83M |
| EffectOfExchangeRateChanges | 67.84K | -19.26K |
| ChangesInCash | -7.89M | 6.13M |
| FinancingCashFlow | 241.94K | 17.56M |
| CashFlowFromContinuingFinancingActivities | 241.94K | 17.56M |
| NetOtherFinancingCharges | 241.94K | -2.44M |
| NetCommonStockIssuance | 0.00 | 20.10M |
| CommonStockIssuance | 0.00 | 20.10M |
| NetIssuancePaymentsOfDebt | 0.00 | -104.50K |
| NetShortTermDebtIssuance | 0.00 | -104.50K |
| ShortTermDebtPayments | 0.00 | -104.50K |
| NetLongTermDebtIssuance | -104.50K | |
| LongTermDebtPayments | -104.50K | |
| LongTermDebtIssuance | 0.00 | |
| InvestingCashFlow | -1.55K | -2.00K |
| CashFlowFromContinuingInvestingActivities | -1.55K | -2.00K |
| NetPPEPurchaseAndSale | -1.55K | -2.00K |
| PurchaseOfPPE | -1.55K | -2.00K |
| OperatingCashFlow | -8.13M | -11.42M |
| CashFlowFromContinuingOperatingActivities | -8.13M | -11.42M |
| ChangeInWorkingCapital | 3.23M | 2.84M |
| ChangeInOtherCurrentLiabilities | 252.51K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 3.01M | 2.94M |
| ChangeInPrepaidAssets | -23.52K | -100.31K |
| OtherNonCashItems | 13.47M | |
| StockBasedCompensation | 351.72K | 669.60K |
| DepreciationAmortizationDepletion | 1.73K | 1.50K |
| DepreciationAndAmortization | 1.73K | 1.50K |
| Depreciation | 1.73K | 1.50K |
| OperatingGainsLosses | -1.46M | |
| GainLossOnInvestmentSecurities | -1.46M | |
| NetIncomeFromContinuingOperations | -11.71M | -26.95M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for SCPS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|